Open main menu

Methandriol (INN) (brand names Anabol, Crestabolic, Cytobolin, Diandren, Durabolic, Madiol, Mestenediol, Methabolic, Methydiol, Sterabolic, Stenediol), also known as methylandrostenediol, as well as 17α-methylandrost-5-ene-3β,17β-diol, is a synthetic, orally active androgen and anabolic steroid (AAS) which was developed by Organon and is used in both oral and injectable (as methandriol dipropionate, methandriol propionate, or methandriol bisenanthoyl acetate) formulations.[1][2][3] It is a 17α-alkylated AAS and the 17α-methylated derivative of the endogenous androgen prohormone androstenediol.[1][2]

Methandriol
Methandriol.svg
Clinical data
Trade namesCrestabolic, Cytobolin, Diandren, Madiol, Stenediol, Mestenediol
Other namesMetandriol; Methylandrostenediol; Methylandrostenediole; 17α-Methylandrost-5-ene-3β,17β-diol
Routes of
administration
By mouth
Drug classAndrogen; Anabolic steroid
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ECHA InfoCard100.007.548 Edit this at Wikidata
Chemical and physical data
FormulaC20H32O2
Molar mass304.474 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Methandriol has been used in the treatment of breast cancer in women.[4][5][6][7] It has been reported to be almost as virilizing as comparable doses of testosterone propionate and methyltestosterone in women.[8]

Methandriol remains marketed for clinical use only in Taiwan and for veterinary use (as methandriol dipropionate) only in Australia.[9]

Methandriol (brand name Androteston M, Notandron, Protandren) was previously marketed as 25 mL and 50 mg/mL aqueous suspensions for use by intramuscular injection.[10]

HistoryEdit

Methandriol was first synthesized in 1935 along with methyltestosterone and mestanolone.[4][11][12]

Androgen/anabolic steroid dosages for breast cancer

Route Medication Form Dosage
Oral Methyltestosterone Tablet 30–200 mg/day
Fluoxymesterone Tablet 10–40 mg 3x/day
Calusterone Tablet 40–80 mg 4x/day
Normethandrone Tablet 40 mg/day
Buccal Methyltestosterone Tablet 25–100 mg/day
Injection (IM or SC) Testosterone propionate Oil solution 50–100 mg 3x/week
Testosterone enanthate Oil solution 200–400 mg 1x/2–4 weeks
Testosterone cypionate Oil solution 200–400 mg 1x/2–4 weeks
Mixed testosterone esters Oil solution 250 mg 1x/week
Methandriol Aqueous suspension 100 mg 3x/week
Androstanolone (DHT) Aqueous suspension 300 mg 3x/week
Drostanolone propionate Oil solution 100 mg 1–3x/week
Metenolone enanthate Oil solution 400 mg 3x/week
Nandrolone decanoate Oil solution 50–100 mg 1x/1–3 weeks
Nandrolone phenylpropionate Oil solution 50–100 mg/week
Note: Dosages are not necessarily equivalent. Sources: See template.

ReferencesEdit

  1. ^ a b J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 794–. ISBN 978-1-4757-2085-3.
  2. ^ a b I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 177–. ISBN 978-94-011-4439-1.
  3. ^ John A. Thomas; Edward J. Keenan (6 December 2012). Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 125–. ISBN 978-1-4684-5036-1.
  4. ^ a b Henderson, Edward; Weinberg, Marvin (1951). "Methylandrostenediol". The Journal of Clinical Endocrinology & Metabolism. 11 (6): 641–652. doi:10.1210/jcem-11-6-641. ISSN 0021-972X.
  5. ^ Homburger, F.; Kasdon, S. C.; Fishman, W. H. (1950). "Methylandrostenediol: A Non-Virilizing Derivative of Testosterone in Metastatic Cancer of the Breast". Experimental Biology and Medicine. 74 (1): 162–164. doi:10.3181/00379727-74-17840. ISSN 1535-3702.
  6. ^ Kasdon, S. C. (1952). "Methylandrostenediol in palliative treatment of breast cancer". JAMA: The Journal of the American Medical Association. 148 (14): 1212. doi:10.1001/jama.1952.02930140044014. ISSN 0098-7484.
  7. ^ Segaloff, Albert; Gordon, Douglas; Horwitt, Benjamin N.; Schlosser, Joseph V.; Murison, Paul J. (1952). "Hormonal therapy in cancer of the breast.II. Effect of methylandrostenediol on clinical course and hormonal excretion". Cancer. 5 (2): 271–274. doi:10.1002/1097-0142(195203)5:2<271::AID-CNCR2820050212>3.0.CO;2-W. ISSN 0008-543X.
  8. ^ Harold Gardiner-Hill (1958). Modern Trends in Endocrinology. Butterworth. p. 235. Foss (1956), using methylandrostenediol in doses of 100 milligrams daily in the treatment of patients with inoperable carcinoma of the breast, found it almost as virilizing as testosterone propionate or methyltestosterone in comparable doses.
  9. ^ https://www.drugs.com/international/methandriol.html
  10. ^ Heinrich Kahr (8 March 2013). Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. Springer-Verlag. pp. 21–. ISBN 978-3-7091-5694-0.
  11. ^ Schänzer W (1996). "Metabolism of anabolic androgenic steroids". Clin. Chem. 42 (7): 1001–20. PMID 8674183.
  12. ^ Ruzicka, L.; Goldberg, M. W.; Rosenberg, H. R. (1935). "Sexualhormone X. Herstellung des 17-Methyl-testosterons und anderer Androsten- und Androstanderivate. Zusammenhänge zwischen chemischer Konstitution und männlicher Hormonwirkung". Helvetica Chimica Acta. 18 (1): 1487–1498. doi:10.1002/hlca.193501801203. ISSN 0018-019X.

External linksEdit